Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy

Administered By

Awarded By

Contributors

Start/End

  • August 1, 2020 - July 31, 2025